A Study of MK-2060 in Participants With Chronic Kidney Disease (MK-2060-011)
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and
pharmacodynamics of a single subcutaneous dose of MK-2060 in stage 4 chronic kidney disease
(CKD4) participants. The primary hypothesis is that the true geometric mean of the area under
the concentration-time curve from 0 to infinity (AUC0-inf) after a single-dose of MK-2060 in
adult CKD4 participants is at least 1130 nM*hr.